Health Catalyst (HCAT) Research & Development (2018 - 2026)

Health Catalyst has reported Research & Development for 9 years, with the latest figure at $9.8 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 35.61% year-over-year to $9.8 million; the trailing twelve-month figure through Mar 2026 stood at $44.4 million (down 23.86% YoY), and the FY2025 full-year result was $49.8 million, down 14.12% from the prior year.
• Research & Development for Q1 2026 stood at $9.8 million, down from $9.9 million in the prior quarter.
• The five-year high for Research & Development was $20.8 million in Q3 2022, with the low at $9.8 million in Q1 2026.
• Historically, Research & Development has averaged $15.6 million across 5 years, with a median of $15.2 million in 2025.
• Annual changes were most pronounced in 2022 — Research & Development advanced 26.76% — and 2026, when it plunged 35.61%.
• Health Catalyst's Research & Development stood at $19.6 million in 2022, then gained by 3.44% to $20.3 million in 2023, then fell by 26.05% to $15.0 million in 2024, then sank by 33.94% to $9.9 million in 2025, then slipped by 1.33% to $9.8 million in 2026.
• The last three Research & Development figures came in at $9.8 million (Q1 2026), $9.9 million (Q4 2025), and $12.3 million (Q3 2025), per Business Quant data.